Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9412783 | 0.80 | TSHR (0.43) | MEN1KMT2ATSHRUSP2ABCB11 | |
| SCHEMBL1707076 | 0.77 | TSHR (0.46) | MEN1KMT2ATSHRUSP2ABCB11 | |
| SCHEMBL9243012 | 0.77 | TSHR (0.46) | MEN1KMT2ATSHRUSP2ABCB11 | |
| SCHEMBL5512678 | 0.75 | TSHR (0.43) | MEN1KMT2ATSHRUSP2ABCB11 | |
| SCHEMBL2478389 | 0.74 | TSHR (0.48) | MEN1KMT2ATSHRUSP2ABCB11 | |
| SCHEMBL6063978 | 0.74 | TSHR (0.48) | MEN1KMT2ATSHRUSP2ABCB11 | |
| SCHEMBL7655973 | 0.73 | TSHR (0.42) | MEN1KMT2ATSHRUSP2ABCB11 | |
| SCHEMBL4675760 | 0.72 | TSHR (0.46) | MEN1KMT2ATSHRUSP2ABCB11 | |
| SCHEMBL4675881 | 0.72 | TSHR (0.46) | MEN1KMT2ATSHRUSP2ABCB11 | |
| SCHEMBL235499 | 0.72 | TSHR (0.46) | MEN1KMT2ATSHRUSP2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2603225-A2 | ELECTRONICALLY MODIFIED REACTION INTERMIDEATES | Markou, Demetrios (US) | 2013-06-19 | — | — | EP | claimed |
| WO-2012024196-A2 | A NOVEL METHOD FOR CREATING, SUSPENDING AND STABILIZING ELECTRONICALLY MODIFIED REACTION INTERMIDEATES | MARKOU DEMETRIOS (US) | 2012-02-23 | — | — | WO | claimed |
| US-20120039796-A1 | Novel method for creating, suspending and stabilizing electronically modified oxygen derivatives, along with creating, suspending and stabilizing electronically modified reaction intermediates, in a bio compatible fluorocarbon suspension, for the purpose of inducing a cascading immune response in mammalian patients | MARKOU DEMETRIOS (US) | 2012-02-16 | — | — | US | claimed |
| EP-2167104-A1 | BIFUNCTIONAL SYNTHETIC MOLECULES | BioChemics, Inc. (US) | 2010-03-31 | — | — | EP | claimed |
| WO-2008156758-A1 | BIFUNCTIONAL SYNTHETIC MOLECULES | BIOCHEMICS, INC. (US) | 2008-12-24 | — | — | WO | claimed |
| US-4631294-A | TRAUMAS, STROKES, CARDIOVASCULAR DISORDERS | UNIVERSITY E.M., INC. (US) | 1986-12-23 | — | — | US | claimed |
| US-10927067-B2 | Organic crystalline salt of haloacetic acid | PARAYIL SARIN (IN) | 2021-02-23 | — | — | US | disclosed |
| US-20200039919-A1 | NOVEL ORGANIC CRYSTALLINE SALT OF HALOACETIC ACID | PARAYIL SARIN (IN) | 2020-02-06 | — | — | US | disclosed |
| WO-2018096517-A1 | NOVEL ORGANIC CRYSTALLINE SALT OF HALOACETIC ACID | PARAYIL SARIN (IN) | 2018-05-31 | — | — | WO | disclosed |
| EP-3116490-A1 | DICHLOROACETATE COMPOUNDS FOR USE IN TREATING A DISEASE CAUSED BY A GLYCOLYTIC PARASITE | Universitat Autònoma De Barcelona (ES) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015135926-A1 | DICHLOROACETATE COMPOUNDS FOR USE IN TREATING A DISEASE CAUSED BY A GLYCOLYTIC PARASITE | UNIVERSITAT AUTONOMA DE BARCELONA (ES) | 2015-09-17 | — | — | WO | disclosed |
| US-20140037760-A1 | METHODS OF INDUCING STASIS FOR THE TREATMENT OF CANCER | THRAMANN JEFF (US) | 2014-02-06 | — | — | US | disclosed |
| US-8609724-B2 | Method of treating cancer using dichloroacetate | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2013-12-17 | — | — | US | disclosed |
| WO-2012126002-A1 | METHODS OF INDUCING STASIS FOR THE TREATMENT OF CANCER | THRAMANN JEFF (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012024196-A2 | A NOVEL METHOD FOR CREATING, SUSPENDING AND STABILIZING ELECTRONICALLY MODIFIED REACTION INTERMIDEATES | MARKOU DEMETRIOS (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20120039796-A1 | Novel method for creating, suspending and stabilizing electronically modified oxygen derivatives, along with creating, suspending and stabilizing electronically modified reaction intermediates, in a bio compatible fluorocarbon suspension, for the purpose of inducing a cascading immune response in mammalian patients | MARKOU DEMETRIOS (US) | 2012-02-16 | — | — | US | disclosed |
| US-20090118370-A1 | METHOD OF TREATING CANCER USING DICHLOROACETATE | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-05-07 | — | — | US | disclosed |
| WO-2006108276-A1 | A METHOD OF TREATING CANCER USING DICHLOROACETATE | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2006-10-19 | — | — | WO | disclosed |
| WO-2002004598-A2 | IMPROVEMENT OF CELL CULTURE PERFORMANCE BY INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE | IMMUNEX CORPORATION (US) | 2002-01-17 | — | — | WO | disclosed |
| US-4631294-A | TRAUMAS, STROKES, CARDIOVASCULAR DISORDERS | UNIVERSITY E.M., INC. (US) | 1986-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927067-B2 | Organic crystalline salt of haloacetic acid | SLC6A6, SLC10A6, REN | MEN1 3353/4885KMT2A 835/4885TSHR 631/4885 |
| US-20140037760-A1 | METHODS OF INDUCING STASIS FOR THE TREATMENT OF CANCER | BAD, HCCS, PTGIS | MEN1 2461/4885KMT2A 1675/4885TSHR 3495/4885 |
| US-20200039919-A1 | NOVEL ORGANIC CRYSTALLINE SALT OF HALOACETIC ACID | SLC6A6, SLC10A6, REN | MEN1 3257/4885KMT2A 1044/4885TSHR 820/4885 |
| US-20090118370-A1 | METHOD OF TREATING CANCER USING DICHLOROACETATE | CCAR2, CASP3, BCL2 | MEN1 2327/4885KMT2A 589/4885TSHR 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.